These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28915903)

  • 1. A quantitative assessment of the evolution of cerebellar syndrome in children with phosphomannomutase-deficiency (PMM2-CDG).
    Serrano NL; De Diego V; Cuadras D; Martinez Monseny AF; Velázquez-Fragua R; López L; Felipe A; Gutiérrez-Solana LG; Macaya A; Pérez-Dueñas B; Serrano M;
    Orphanet J Rare Dis; 2017 Sep; 12(1):155. PubMed ID: 28915903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.
    Serrano M; de Diego V; Muchart J; Cuadras D; Felipe A; Macaya A; Velázquez R; Poo MP; Fons C; O'Callaghan MM; García-Cazorla A; Boix C; Robles B; Carratalá F; Girós M; Briones P; Gort L; Artuch R; Pérez-Cerdá C; Jaeken J; Pérez B; Pérez-Dueñas B
    Orphanet J Rare Dis; 2015 Oct; 10():138. PubMed ID: 26502900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG).
    Martínez-Monseny AF; Bolasell M; Callejón-Póo L; Cuadras D; Freniche V; Itzep DC; Gassiot S; Arango P; Casas-Alba D; de la Morena E; Corral J; Montero R; Pérez-Cerdá C; Pérez B; Artuch R; Jaeken J; Serrano M;
    Ann Neurol; 2019 May; 85(5):740-751. PubMed ID: 30873657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Assessment of Dysarthria in Children with Cerebellar Syndrome Associated with PMM2-CDG.
    Itzep D; Martínez-Monseny AF; Bolasell M; Cuadras D; Velázquez-Fragua R; Gutierrez-Solana LG; Macaya A; Pérez-Dueñas B; Serrano M;
    Neuropediatrics; 2018 Dec; 49(6):408-413. PubMed ID: 30304743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal volumetric and 2D assessment of cerebellar atrophy in a large cohort of children with phosphomannomutase deficiency (PMM2-CDG).
    de Diego V; Martínez-Monseny AF; Muchart J; Cuadras D; Montero R; Artuch R; Pérez-Cerdá C; Pérez B; Pérez-Dueñas B; Poretti A; Serrano M;
    J Inherit Metab Dis; 2017 Sep; 40(5):709-713. PubMed ID: 28341975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and radiological correlates of activities of daily living in cerebellar atrophy caused by PMM2 mutations (PMM2-CDG).
    Pettinato F; Mostile G; Battini R; Martinelli D; Madeo A; Biamino E; Frattini D; Garozzo D; Gasperini S; Parini R; Sirchia F; Sortino G; Sturiale L; Matthijs G; Morrone A; Di Rocco M; Rizzo R; Jaeken J; Fiumara A; Barone R
    Cerebellum; 2021 Aug; 20(4):596-605. PubMed ID: 33619652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke-Like Episodes and Cerebellar Syndrome in Phosphomannomutase Deficiency (PMM2-CDG): Evidence for Hypoglycosylation-Driven Channelopathy.
    Izquierdo-Serra M; Martínez-Monseny AF; López L; Carrillo-García J; Edo A; Ortigoza-Escobar JD; García Ó; Cancho-Candela R; Carrasco-Marina ML; Gutiérrez-Solana LG; Cuadras D; Muchart J; Montero R; Artuch R; Pérez-Cerdá C; Pérez B; Pérez-Dueñas B; Macaya A; Fernández-Fernández JM; Serrano M
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29470411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.
    Schiff M; Roda C; Monin ML; Arion A; Barth M; Bednarek N; Bidet M; Bloch C; Boddaert N; Borgel D; Brassier A; Brice A; Bruneel A; Buissonnière R; Chabrol B; Chevalier MC; Cormier-Daire V; De Barace C; De Maistre E; De Saint-Martin A; Dorison N; Drouin-Garraud V; Dupré T; Echenne B; Edery P; Feillet F; Fontan I; Francannet C; Labarthe F; Gitiaux C; Héron D; Hully M; Lamoureux S; Martin-Coignard D; Mignot C; Morin G; Pascreau T; Pincemaille O; Polak M; Roubertie A; Thauvin-Robinet C; Toutain A; Viot G; Vuillaumier-Barrot S; Seta N; De Lonlay P
    J Med Genet; 2017 Dec; 54(12):843-851. PubMed ID: 28954837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directions.
    Muthusamy K; Perez-Ortiz JM; Ligezka AN; Altassan R; Johnsen C; Schultz MJ; Patterson MC; Morava E
    Genet Med; 2024 Feb; 26(2):101027. PubMed ID: 37955240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From gestalt to gene: early predictive dysmorphic features of PMM2-CDG.
    Martinez-Monseny A; Cuadras D; Bolasell M; Muchart J; Arjona C; Borregan M; Algrabli A; Montero R; Artuch R; Velázquez-Fragua R; Macaya A; Pérez-Cerdá C; Pérez-Dueñas B; Pérez B; Serrano M;
    J Med Genet; 2019 Apr; 56(4):236-245. PubMed ID: 30464053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype.
    Monin ML; Mignot C; De Lonlay P; Héron B; Masurel A; Mathieu-Dramard M; Lenaerts C; Thauvin C; Gérard M; Roze E; Jacquette A; Charles P; de Baracé C; Drouin-Garraud V; Khau Van Kien P; Cormier-Daire V; Mayer M; Ogier H; Brice A; Seta N; Héron D
    Orphanet J Rare Dis; 2014 Dec; 9():207. PubMed ID: 25497157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG).
    Taday R; Grüneberg M; DuChesne I; Reunert J; Marquardt T
    Orphanet J Rare Dis; 2020 Sep; 15(1):258. PubMed ID: 32962735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reliability and validity of ICARS in focal cerebellar lesions.
    Schoch B; Regel JP; Frings M; Gerwig M; Maschke M; Neuhäuser M; Timmann D
    Mov Disord; 2007 Nov; 22(15):2162-9. PubMed ID: 17712842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary ovarian insufficiency in a female with phosphomannomutase-2 gene (PMM2) mutations for congenital disorder of glycosylation.
    Masunaga Y; Mochizuki M; Kadoya M; Wada Y; Okamoto N; Fukami M; Kato F; Saitsu H; Ogata T
    Endocr J; 2021 May; 68(5):605-611. PubMed ID: 33583911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
    Ligezka AN; Radenkovic S; Saraswat M; Garapati K; Ranatunga W; Krzysciak W; Yanaihara H; Preston G; Brucker W; McGovern RM; Reid JM; Cassiman D; Muthusamy K; Johnsen C; Mercimek-Andrews S; Larson A; Lam C; Edmondson AC; Ghesquière B; Witters P; Raymond K; Oglesbee D; Pandey A; Perlstein EO; Kozicz T; Morava E
    Ann Neurol; 2021 Dec; 90(6):887-900. PubMed ID: 34652821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal involvement in PMM2-CDG, a mini-review.
    Altassan R; Witters P; Saifudeen Z; Quelhas D; Jaeken J; Levtchenko E; Cassiman D; Morava E
    Mol Genet Metab; 2018 Mar; 123(3):292-296. PubMed ID: 29229467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypes and estimated prevalence of phosphomannomutase 2 deficiency in Turkey differ significantly from those in Europe.
    Yıldız Y; Arslan M; Çelik G; Kasapkara ÇS; Ceylaner S; Dursun A; Sivri HS; Coşkun T; Tokatlı A
    Am J Med Genet A; 2020 Apr; 182(4):705-712. PubMed ID: 31981409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation.
    Barone R; Carrozzi M; Parini R; Battini R; Martinelli D; Elia M; Spada M; Lilliu F; Ciana G; Burlina A; Leuzzi V; Leoni M; Sturiale L; Matthijs G; Jaeken J; Di Rocco M; Garozzo D; Fiumara A
    J Neurol; 2015 Jan; 262(1):154-64. PubMed ID: 25355454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.
    Altassan R; Péanne R; Jaeken J; Barone R; Bidet M; Borgel D; Brasil S; Cassiman D; Cechova A; Coman D; Corral J; Correia J; de la Morena-Barrio ME; de Lonlay P; Dos Reis V; Ferreira CR; Fiumara A; Francisco R; Freeze H; Funke S; Gardeitchik T; Gert M; Girad M; Giros M; Grünewald S; Hernández-Caselles T; Honzik T; Hutter M; Krasnewich D; Lam C; Lee J; Lefeber D; Marques-de-Silva D; Martinez AF; Moravej H; Õunap K; Pascoal C; Pascreau T; Patterson M; Quelhas D; Raymond K; Sarkhail P; Schiff M; Seroczyńska M; Serrano M; Seta N; Sykut-Cegielska J; Thiel C; Tort F; Vals MA; Videira P; Witters P; Zeevaert R; Morava E
    J Inherit Metab Dis; 2019 Jan; 42(1):5-28. PubMed ID: 30740725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three families with mild PMM2-CDG and normal cognitive development.
    Vals MA; Morava E; Teeäär K; Zordania R; Pajusalu S; Lefeber DJ; Õunap K
    Am J Med Genet A; 2017 Jun; 173(6):1620-1624. PubMed ID: 28425223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.